Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

被引：66
|
作者：
Selvan, Senthamil R. [1 ]
Dowling, John P. [2 ]
Kelly, William K. [1 ]
Lin, Jianqing [1 ]
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Immunol & Microbial Pathogenesis Grad Program, Philadelphia, PA 19107 USA
来源：
CURRENT CANCER DRUG TARGETS | 2016年 / 16卷 / 09期
关键词：
Cancer immunotherapy; combination therapy; indoleamine 2,3-dioxygenase (IDO); IDO inhibitors; immune tolerance; REGULATORY T-CELLS; NATURAL-KILLER-CELLS; PLASMACYTOID DENDRITIC CELLS; TUMOR-INFILTRATING LYMPHOCYTES; BLOOD MONONUCLEAR-CELLS; DRAINING LYMPH-NODES; SUPPRESSOR-CELLS; PERIPHERAL-BLOOD; LUNG-CANCER; TRYPTOPHAN CATABOLISM;
D O I：
10.2174/1568009615666151030102250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
引用
收藏
页码：755 / 764
页数：10
相关论文
共 50 条
  • [31] The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
    Gao, Yan-Fang
    Peng, Rui-Qing
    Li, Jiang
    Ding, Ya
    Zhang, Xing
    Wu, Xiao-Jun
    Pan, Zhi-Zhong
    Wan, De-Sen
    Zeng, Yi-Xin
    Zhang, Xiao-Shi
    JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
  • [32] Role of indoleamine 2,3-dioxygenase in health and disease
    Yeung, Amanda W. S.
    Terentis, Andrew C.
    King, Nicholas J. C.
    Thomas, Shane R.
    CLINICAL SCIENCE, 2015, 129 (07) : 601 - 672
  • [33] Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
    Huang, Guanyou
    Zeng, Yaoying
    Liang, Peiyan
    Zhou, Congrong
    Zhao, Shuyun
    Huang, Xiuyan
    Wu, Lingfei
    He, Xianhui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (09) : 10863 - 10879
  • [34] Indoleamine 2,3-dioxygenase in the pathogenesis of tuberculous pleurisy
    Suzuki, Y.
    Miwa, S.
    Akamatsu, T.
    Suzuki, M.
    Fujie, M.
    Nakamura, Y.
    Inui, N.
    Hayakawa, H.
    Chida, K.
    Suda, T.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (11) : 1501 - 1506
  • [35] No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients
    Bigenzahn, S.
    Juergens, B.
    Mahr, B.
    Pratschke, J.
    Koenigsrainer, A.
    Becker, T.
    Fuchs, D.
    Brandacher, G.
    Kainz, A.
    Muehlbacher, F.
    Wekerle, T.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 192 (02) : 233 - 241
  • [36] Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
    Antonio Macchiarulo
    Emidio Camaioni
    Roberto Nuti
    Roberto Pellicciari
    Amino Acids, 2009, 37 : 219 - 229
  • [37] Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
    Macchiarulo, Antonio
    Camaioni, Emidio
    Nuti, Roberto
    Pellicciari, Roberto
    AMINO ACIDS, 2009, 37 (02) : 219 - 229
  • [38] Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
    Prendergast, George C.
    Malachowski, William J.
    Mondal, Arpita
    Scherle, Peggy
    Muller, Alexander J.
    INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 336, 2018, 336 : 175 - 203
  • [39] Indoleamine 2,3-dioxygenase (IDO) Activity in Placental Compartments of Renal-Transplanted Pregnant Women
    do Prado, Karen Matias
    Correa-Silva, Simone
    Oliveira, Leandro Gustavo
    Saraiva Camara, Niels Olsen
    Ono, Erica
    Sandri, Silvana
    Tourino, Melissa Cavalheiro
    Campa, Ana
    Lima, Larissa de Sa
    Scavone, Cristoforo
    Bevilacqua, Estela
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 72 (01) : 45 - 56
  • [40] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
    Moyer, Benjamin J.
    Rojas, Itzel Y.
    Murray, Iain A.
    Lee, Seokwon
    Hazlett, Haley F.
    Perdew, Gary H.
    Tomlinson, Craig R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 323 : 74 - 80
12345